Risikoen for CHD dødsfald blev reduceret med 42% (absolut risikoreduktion på 3, 5%). < Zocord > reducerede også risikoen for alvorligere koronare hændelser (CHD dødsfald samt hospitalsverificeret og ikke- symptomgivende non- fatal MI) med 34%.
The risk of CHD death was reduced by 42% (absolute risk reduction of 3.5%) .< Zocord > also decreased the risk of having major coronary events (CHD death plus hospital-verified and silent nonfatal MI) by 34%.